-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chimeric antigen receptor T cell (CAR-T) therapy, as a disruptive innovative therapy, is booming in China
.
On June 22, 2021, Yikaida® (Akilunza injection) was officially approved by the National Medical Products Administration (NMPA), becoming China’s first CAR-T therapy drug targeting CD19 for the treatment of previously accepted drugs Adult patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) after second-line or above systemic treatment bring new treatment options for R/R LBCL
.
At present, it has been approved in 38 countries around the world, and has accumulated nearly 5,000 patient experience
.
In order to promote the development of China's CAR-T field, build China's CAR-T star treatment center, and cooperate with international and domestic diagnosis and treatment
.
"CCSC (China CAR-T Star Center)-Kylinhui International Connection" continues! The new phase of Kylin Club International Connection was successfully held
.
This conference is fortunate to invite Professor Wu Depei from the First Affiliated Hospital of Soochow University, Professor Wen-Kai Weng from Stanford School of Medicine, Professor Li Caixia from the First Affiliated Hospital of Soochow University, Dr.
Zhang Ying from the First Affiliated Hospital of Soochow University, and many top domestic experts to serve as the conference Speakers and discussion guests focused on cutting-edge topics in the field of CAR-T cell therapy, and conducted in-depth discussions and exchanges on Fosun Kate's CAR-T cell therapy drug Yikaida® (Akirensai Injection)
.
Below, I will take you to review the wonderful links of this conference.
I hope that this conference can expand clinicians' understanding of the clinical efficacy of Akirensai injection and further improve the clinical benefits of patients
.
Comprehensive analysis of CAR-T cell therapy from mechanism to real-world curative effect In this session, Professor Wen-Kai Weng gave a speech entitled "CAR-T Therapy: The Future is Here" to share
.
Professor Wen-Kai Weng first gave a brief introduction to the common fields of cell therapy and traditional treatment methods.
Among them, CAR-T cell therapy is currently a more complex technology.
It is used in the treatment of lymphoma, leukemia and myeloma.
application, the site of action include CD19, CD22, CD70, CD30, CD7, CD38, CLL1, BCMA and the like
.
An important drug for CAR-T cell therapy is Akirensai injection, which is currently approved by the FDA for R/R LBCL patients
.
Subsequently, Professor Wen-Kai Weng gave a detailed introduction to the process, specific cases and specific effects of CAR-T cell therapy
.
In the ZUMA-1 study, a 65-year-old male patient with diffuse large B-cell lymphoma (DLBCL) relapsed 6 months after transplantation and achieved complete remission (CR) after treatment with CAR-T cells without cytokines Release syndrome (CRS) and immune effector cell-related neurotoxicity syndrome (ICANS) occur
.
Based on the results of the current study, it can be seen that the overall response rate (ORR) of CAR-T cell therapy can reach 83%, the CR rate can reach 58%, the median overall survival (OS) can reach 25.
8 months, and the 4-year OS rate can be Reach 44%
.
In addition, Professor Wen-Kai Weng also compared the current three CD19 CAR-T cell therapy drugs in terms of mechanism, efficacy and safety.
It can be seen that the superiority of Akirensai injection in terms of efficacy, but in Security needs to be strengthened
.
It should be noted that toxicity is related to changes in the number of cells after infusion.
CRS should be classified and processed, and monitoring should be strengthened 30 days after infusion
.
Finally, Professor Wen-Kai Weng made several suggestions on the use of CAR-T cell therapy in the real world
.
First, because the tumor size is closely related to the efficacy, it is recommended to use CAR-T therapy as soon as possible; second, for bridging treatment, which is still controversial, dexamethasone is recommended; third, for patients with loss of CD19 target, it can be combined with other treatments The target is CD22, CD20 or CD79b; the fourth is the prediction of curative effect, the increase of lactate dehydrogenase (LDH) is a significant related factor
.
Professor Wen-Kai Weng also gave a brief introduction to the latest study on the use of CAR-T cell therapy in the second line of R/R LBCL patients.
The results of the study showed that the median OS was not reached and the safety was manageable
.
In summary, Professor Wen-Kai Weng believes that CD19 CAR-T cell therapy is the preferred treatment for R/R LBCL patients
.
Introduction of Suzhou Hematology Center In this session, Professor Chen Jia, assistant director of the Department of Hematology of the First Affiliated Hospital of Soochow University, gave a brief introduction to Suzhou Hematology Center
.
From the establishment of the Suzhou Department of Hematology in 1953, after decades of development, to the establishment of the Jiangsu Provincial Institute of Hematology in 1988
.
The research center includes 4 research institutions, namely the Clinical Hematology Department, the Clinical Blood Laboratory, the Down's Blood Research Center and the Institute of Hematopoietic Stem Cell Transplantation
.
Currently, there are three main research directions, namely thrombosis and hemostasis, hematological malignancies (leukemia, lymphoma), and transplantation and cell therapy
.
The research center is in a period of rapid development, and the number of outpatient clinics and hospitalizations is constantly increasing
.
The number of hematopoietic stem cell transplants is increasing year by year.
In 2020, 813 hematopoietic stem cell transplants (including autologous hematopoietic stem cell transplantation and allogeneic hematopoietic stem cell transplantation) were carried out, and more than 800 cases of CAR-T treatment experience
.
In-depth analysis of the first case of CAR-T cell therapy in China
.
In this session, Dr.
Ying Zhang gave a speech entitled "The First Patients with R/R DLBCL Treated by Yescarta in China" .
First, Dr.
Zhang Ying gave a summary and introduction to the research of Suzhou Hematology Center using CAR-T cells to treat B-cell lymphoma (B-NHL)
.
A total of 136 R/R B-NHL patients were included in the treatment from 2017 to 2021.
The results of the study showed that the median follow-up time was 11.
7 months, the ORR was 77.
6%, the 5-year OS rate was 63.
8%, and the 5-year progression-free survival (PFS) ) The rate is 48.
3%
.
Then Dr.
Zhang Ying introduced a 57-year-old male patient with R/R DLBCL who was treated with CAR-T
.
From December 7, 2020 to April 21, 2021, the patient experienced 3 different chemotherapy regimens and his disease progressed and was transferred to Suzhou Hematology Center for treatment
.
The patient met the indications for CAR-T treatment and received CAR-T cell therapy from July 5 to August 3, 2021.
After 28 days, the pancreas tumor was absorbed and the spleen tumor shrank.
After 3 months, the patient relapsed and the spleen tumor enlarged
.
The participating experts discussed the sharing of Professor Wen-Kai Weng and Dr.
Zhang Ying
.
Dr.
Zhang Ying raised questions about the timing of re-intervention when patients reach PR after CAR-T treatment and other indicators that predict efficacy except LDH
.
Professor Wen-Kai Weng said that excessive LDH is a risk factor for disease recurrence.
It is controversial whether patients with residual disease should be treated with CAR-T again.
It is recommended that patients undergo transplantation or use CD22 CAR-T therapy; indicators for predicting efficacy , You can also use circulating DNA
.
For the detection of immune function after CAR-T treatment, Professor Wen-Kai Weng recommends the detection of CD4 and CD19
.
Professor Xu Ting from the First Affiliated Hospital of Soochow University raised questions about the correlation between the high efficacy and high toxicity of CAR-T cell therapy, the use of hormones and radiotherapy for bridging therapy, and the influence of age on the efficacy
.
Professor Wen-Kai Weng said that the efficacy and toxicity are not completely synchronized, but toxicity and tumor burden are significantly related; the use of hormones is only used for patients with local symptoms and will not be used for too long.
At present, it is more effective For the use of radiotherapy, there is no need to wait too long, and the treatment time is shorter; for the benefit of elderly patients, the efficacy will not be significantly reduced due to older age, but the time for disease recovery will be prolonged
.
Professor Zong Xiangping from the First Affiliated Hospital of Soochow University raised questions about the drugs used to reduce tumor burden and the occurrence of hematological toxicity in bridging treatment
.
Professor Wen-Kai Weng said that apart from hormones, there are currently no recommendations for other drugs.
Regarding hematological toxicity, the incidence is not high, but once it occurs, it will last for a longer period of time.
You can try hormone therapy
.
Professor Li Caixia said that PD-1 inhibitors can be given to try the treatment after CAR-T treatment
.
Professor Zhou Jin from the First Affiliated Hospital of Soochow University raised questions about the use of ranalidomide for maintenance therapy in high-risk relapsed patients and the use of CD19 CAR-T for patients who are intolerant of chemotherapy
.
Professor Wen-Kai Weng said that there is little clinical experience in this area and further research is needed
.
Professor Li Caixia raised questions about more treatment options for relapsed patients
.
Professor Wen-Kai Weng said that various treatment methods can be tried for salvage treatment, but in the end, transplantation is recommended.
Observing transplantation does not increase the risk of graft-versus-host disease (GVHD) in patients
.
In the end, Professor Li Caixia expressed his gratitude to Professor Wen-Kai Weng for sharing, and hoped to have more exchanges on CAR-T therapy, so that the top international scientific research results can guide the development of China's CAR-T therapy.
Improve and improve the technology of refractory lymphoma and other hematological malignancies, and work together to achieve long-term and good survival benefits for patients! Poke "read the original text", we make progress together
.
On June 22, 2021, Yikaida® (Akilunza injection) was officially approved by the National Medical Products Administration (NMPA), becoming China’s first CAR-T therapy drug targeting CD19 for the treatment of previously accepted drugs Adult patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) after second-line or above systemic treatment bring new treatment options for R/R LBCL
.
At present, it has been approved in 38 countries around the world, and has accumulated nearly 5,000 patient experience
.
In order to promote the development of China's CAR-T field, build China's CAR-T star treatment center, and cooperate with international and domestic diagnosis and treatment
.
"CCSC (China CAR-T Star Center)-Kylinhui International Connection" continues! The new phase of Kylin Club International Connection was successfully held
.
This conference is fortunate to invite Professor Wu Depei from the First Affiliated Hospital of Soochow University, Professor Wen-Kai Weng from Stanford School of Medicine, Professor Li Caixia from the First Affiliated Hospital of Soochow University, Dr.
Zhang Ying from the First Affiliated Hospital of Soochow University, and many top domestic experts to serve as the conference Speakers and discussion guests focused on cutting-edge topics in the field of CAR-T cell therapy, and conducted in-depth discussions and exchanges on Fosun Kate's CAR-T cell therapy drug Yikaida® (Akirensai Injection)
.
Below, I will take you to review the wonderful links of this conference.
I hope that this conference can expand clinicians' understanding of the clinical efficacy of Akirensai injection and further improve the clinical benefits of patients
.
Comprehensive analysis of CAR-T cell therapy from mechanism to real-world curative effect In this session, Professor Wen-Kai Weng gave a speech entitled "CAR-T Therapy: The Future is Here" to share
.
Professor Wen-Kai Weng first gave a brief introduction to the common fields of cell therapy and traditional treatment methods.
Among them, CAR-T cell therapy is currently a more complex technology.
It is used in the treatment of lymphoma, leukemia and myeloma.
application, the site of action include CD19, CD22, CD70, CD30, CD7, CD38, CLL1, BCMA and the like
.
An important drug for CAR-T cell therapy is Akirensai injection, which is currently approved by the FDA for R/R LBCL patients
.
Subsequently, Professor Wen-Kai Weng gave a detailed introduction to the process, specific cases and specific effects of CAR-T cell therapy
.
In the ZUMA-1 study, a 65-year-old male patient with diffuse large B-cell lymphoma (DLBCL) relapsed 6 months after transplantation and achieved complete remission (CR) after treatment with CAR-T cells without cytokines Release syndrome (CRS) and immune effector cell-related neurotoxicity syndrome (ICANS) occur
.
Based on the results of the current study, it can be seen that the overall response rate (ORR) of CAR-T cell therapy can reach 83%, the CR rate can reach 58%, the median overall survival (OS) can reach 25.
8 months, and the 4-year OS rate can be Reach 44%
.
In addition, Professor Wen-Kai Weng also compared the current three CD19 CAR-T cell therapy drugs in terms of mechanism, efficacy and safety.
It can be seen that the superiority of Akirensai injection in terms of efficacy, but in Security needs to be strengthened
.
It should be noted that toxicity is related to changes in the number of cells after infusion.
CRS should be classified and processed, and monitoring should be strengthened 30 days after infusion
.
Finally, Professor Wen-Kai Weng made several suggestions on the use of CAR-T cell therapy in the real world
.
First, because the tumor size is closely related to the efficacy, it is recommended to use CAR-T therapy as soon as possible; second, for bridging treatment, which is still controversial, dexamethasone is recommended; third, for patients with loss of CD19 target, it can be combined with other treatments The target is CD22, CD20 or CD79b; the fourth is the prediction of curative effect, the increase of lactate dehydrogenase (LDH) is a significant related factor
.
Professor Wen-Kai Weng also gave a brief introduction to the latest study on the use of CAR-T cell therapy in the second line of R/R LBCL patients.
The results of the study showed that the median OS was not reached and the safety was manageable
.
In summary, Professor Wen-Kai Weng believes that CD19 CAR-T cell therapy is the preferred treatment for R/R LBCL patients
.
Introduction of Suzhou Hematology Center In this session, Professor Chen Jia, assistant director of the Department of Hematology of the First Affiliated Hospital of Soochow University, gave a brief introduction to Suzhou Hematology Center
.
From the establishment of the Suzhou Department of Hematology in 1953, after decades of development, to the establishment of the Jiangsu Provincial Institute of Hematology in 1988
.
The research center includes 4 research institutions, namely the Clinical Hematology Department, the Clinical Blood Laboratory, the Down's Blood Research Center and the Institute of Hematopoietic Stem Cell Transplantation
.
Currently, there are three main research directions, namely thrombosis and hemostasis, hematological malignancies (leukemia, lymphoma), and transplantation and cell therapy
.
The research center is in a period of rapid development, and the number of outpatient clinics and hospitalizations is constantly increasing
.
The number of hematopoietic stem cell transplants is increasing year by year.
In 2020, 813 hematopoietic stem cell transplants (including autologous hematopoietic stem cell transplantation and allogeneic hematopoietic stem cell transplantation) were carried out, and more than 800 cases of CAR-T treatment experience
.
In-depth analysis of the first case of CAR-T cell therapy in China
.
In this session, Dr.
Ying Zhang gave a speech entitled "The First Patients with R/R DLBCL Treated by Yescarta in China" .
First, Dr.
Zhang Ying gave a summary and introduction to the research of Suzhou Hematology Center using CAR-T cells to treat B-cell lymphoma (B-NHL)
.
A total of 136 R/R B-NHL patients were included in the treatment from 2017 to 2021.
The results of the study showed that the median follow-up time was 11.
7 months, the ORR was 77.
6%, the 5-year OS rate was 63.
8%, and the 5-year progression-free survival (PFS) ) The rate is 48.
3%
.
Then Dr.
Zhang Ying introduced a 57-year-old male patient with R/R DLBCL who was treated with CAR-T
.
From December 7, 2020 to April 21, 2021, the patient experienced 3 different chemotherapy regimens and his disease progressed and was transferred to Suzhou Hematology Center for treatment
.
The patient met the indications for CAR-T treatment and received CAR-T cell therapy from July 5 to August 3, 2021.
After 28 days, the pancreas tumor was absorbed and the spleen tumor shrank.
After 3 months, the patient relapsed and the spleen tumor enlarged
.
The participating experts discussed the sharing of Professor Wen-Kai Weng and Dr.
Zhang Ying
.
Dr.
Zhang Ying raised questions about the timing of re-intervention when patients reach PR after CAR-T treatment and other indicators that predict efficacy except LDH
.
Professor Wen-Kai Weng said that excessive LDH is a risk factor for disease recurrence.
It is controversial whether patients with residual disease should be treated with CAR-T again.
It is recommended that patients undergo transplantation or use CD22 CAR-T therapy; indicators for predicting efficacy , You can also use circulating DNA
.
For the detection of immune function after CAR-T treatment, Professor Wen-Kai Weng recommends the detection of CD4 and CD19
.
Professor Xu Ting from the First Affiliated Hospital of Soochow University raised questions about the correlation between the high efficacy and high toxicity of CAR-T cell therapy, the use of hormones and radiotherapy for bridging therapy, and the influence of age on the efficacy
.
Professor Wen-Kai Weng said that the efficacy and toxicity are not completely synchronized, but toxicity and tumor burden are significantly related; the use of hormones is only used for patients with local symptoms and will not be used for too long.
At present, it is more effective For the use of radiotherapy, there is no need to wait too long, and the treatment time is shorter; for the benefit of elderly patients, the efficacy will not be significantly reduced due to older age, but the time for disease recovery will be prolonged
.
Professor Zong Xiangping from the First Affiliated Hospital of Soochow University raised questions about the drugs used to reduce tumor burden and the occurrence of hematological toxicity in bridging treatment
.
Professor Wen-Kai Weng said that apart from hormones, there are currently no recommendations for other drugs.
Regarding hematological toxicity, the incidence is not high, but once it occurs, it will last for a longer period of time.
You can try hormone therapy
.
Professor Li Caixia said that PD-1 inhibitors can be given to try the treatment after CAR-T treatment
.
Professor Zhou Jin from the First Affiliated Hospital of Soochow University raised questions about the use of ranalidomide for maintenance therapy in high-risk relapsed patients and the use of CD19 CAR-T for patients who are intolerant of chemotherapy
.
Professor Wen-Kai Weng said that there is little clinical experience in this area and further research is needed
.
Professor Li Caixia raised questions about more treatment options for relapsed patients
.
Professor Wen-Kai Weng said that various treatment methods can be tried for salvage treatment, but in the end, transplantation is recommended.
Observing transplantation does not increase the risk of graft-versus-host disease (GVHD) in patients
.
In the end, Professor Li Caixia expressed his gratitude to Professor Wen-Kai Weng for sharing, and hoped to have more exchanges on CAR-T therapy, so that the top international scientific research results can guide the development of China's CAR-T therapy.
Improve and improve the technology of refractory lymphoma and other hematological malignancies, and work together to achieve long-term and good survival benefits for patients! Poke "read the original text", we make progress together
